Related Experiment Video

Updated: Jul 7, 2026

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer
10:36

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

Unraveling the complexity of endocrine resistance in breast cancer by functional genomics

Charles Swanton1, Julian Downward

  • 1Cancer Research UK London Research Institute, Signal Transduction Laboratory, 44 Lincoln's Inn Fields, London WC2A 3PX, UK. swanton@cancer.org.uk <swanton@cancer.org.uk>

Cancer Cell
|February 5, 2008
PubMed

Insights

Loss of CDK10 expression in breast cancer cells promotes resistance to tamoxifen, a common antiestrogen drug. This finding suggests CDK10 may serve as a biomarker for endocrine therapy effectiveness.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Antiestrogen drugs are crucial for breast cancer treatment, but drug resistance is a significant clinical challenge.
  • Understanding the molecular mechanisms underlying endocrine resistance is vital for improving patient outcomes.

Purpose of the Study:

  • To investigate the role of Cyclin-Dependent Kinase 10 (CDK10) in tamoxifen resistance in breast cancer.
  • To identify potential biomarkers for predicting patient response to endocrine therapies.

Main Methods:

  • The study examined the expression levels of CDK10 in breast cancer cells and patient samples.
  • Researchers analyzed the impact of CDK10 loss on cell cycle progression and signaling pathways, including ETS2 and ERK/MAPK.
  • Correlation between CDK10 expression and patient outcomes in tamoxifen-treated breast cancer was assessed.

Main Results:

  • Loss of CDK10 expression was found to confer resistance to tamoxifen in breast cancer cells.
  • CDK10 deficiency led to increased activity of the transcription factor ETS2 at the RAF1 promoter.
  • This resulted in elevated ERK/MAPK pathway signaling, overcoming tamoxifen-induced cell cycle arrest.
  • Low CDK10 expression correlated with poorer outcomes in patients treated with tamoxifen.

Conclusions:

  • CDK10 plays a critical role in maintaining sensitivity to tamoxifen in breast cancer.
  • Loss of CDK10 promotes endocrine resistance by modulating the ETS2-RAF1-ERK/MAPK axis.
  • CDK10 is a potential predictive biomarker for patient response to endocrine therapy in clinical settings.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...